The Acute Leukaemias:@0.703132:0.035749:0.914567:0.035749:0.914567:0.019993:0.703132:0.019993:0.008197:0.011738:0.012508:0.005330:0.014239:0.012450:0.011699:0.006523:0.012508:0.005330:0.008890:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.007466
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
81:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
twice  daily for four  days). Patients  with :@0.084242:0.096166:0.480490:0.096166:0.480490:0.080410:0.084242:0.080410:0.006523:0.015990:0.003848:0.012450:0.012508:0.005330:0.005821:0.013181:0.013143:0.003848:0.003848:0.010314:0.011161:0.006042:0.012604:0.005782:0.011161:0.006042:0.012604:0.011699:0.005792:0.005330:0.005809:0.013181:0.013143:0.010314:0.007466:0.007100:0.005330:0.011161:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005821:0.015990:0.003848:0.006523:0.011738:0.005330
intermediate and unfavourable cytoge-:@0.084242:0.112517:0.475152:0.112517:0.475152:0.096761:0.084242:0.096761:0.003848:0.011738:0.006523:0.012508:0.006319:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.010814:0.013143:0.011738:0.013181:0.010814:0.011699:0.011738:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.010814:0.012450:0.010314:0.006523:0.012604:0.012950:0.012481:0.006388
netics will benefit from intensification with :@0.084242:0.128868:0.480482:0.128868:0.480482:0.113112:0.084242:0.113112:0.011738:0.012508:0.006523:0.003848:0.012450:0.007466:0.007045:0.015990:0.003848:0.003848:0.003848:0.007056:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.007039:0.006042:0.005711:0.012604:0.018049:0.007041:0.003848:0.011738:0.006523:0.012508:0.011738:0.007466:0.003848:0.004686:0.004686:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007037:0.015990:0.003848:0.006523:0.011738:0.005330
allogeneic stem-cell transplantation from :@0.084242:0.145219:0.480486:0.145219:0.480486:0.129463:0.084242:0.129463:0.013143:0.003848:0.003848:0.012604:0.012950:0.012508:0.011738:0.012508:0.003848:0.012450:0.008197:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.008197:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.008184:0.006042:0.005713:0.012604:0.018049:0.005330
an HLA identical donor. Patients in sec-:@0.084242:0.161571:0.475154:0.161571:0.475154:0.145815:0.084242:0.145815:0.013143:0.011738:0.010218:0.013143:0.008890:0.014239:0.010218:0.003848:0.013181:0.012508:0.011738:0.006523:0.003848:0.012450:0.013143:0.003848:0.010218:0.013181:0.012604:0.011738:0.012604:0.004370:0.005330:0.010218:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.010218:0.003848:0.011738:0.010218:0.007466:0.012508:0.012450:0.006388
ond  remission should also be considered :@0.084242:0.177922:0.480501:0.177922:0.480501:0.162166:0.084242:0.162166:0.012604:0.011738:0.013181:0.005330:0.003008:0.005713:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.008351:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.008351:0.013143:0.003848:0.007466:0.012604:0.008351:0.013123:0.012508:0.008351:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.005330
for this procedure. The chance of having :@0.084242:0.194273:0.480501:0.194273:0.480501:0.178517:0.084242:0.178517:0.006042:0.012604:0.005792:0.007143:0.006523:0.011738:0.003848:0.007466:0.007158:0.013123:0.005715:0.012604:0.012450:0.012508:0.013181:0.011699:0.005711:0.012508:0.005330:0.007147:0.008197:0.011738:0.012508:0.007143:0.012450:0.011738:0.013143:0.011738:0.012450:0.012508:0.007158:0.012604:0.006042:0.007147:0.011738:0.013143:0.010660:0.003848:0.011738:0.012950:0.005330
an HLA-compatible donor  ranges from :@0.084242:0.210624:0.480499:0.210624:0.480499:0.194868:0.084242:0.194868:0.013143:0.011738:0.013066:0.013143:0.008890:0.014239:0.006388:0.012450:0.012604:0.018049:0.013123:0.013143:0.006523:0.003848:0.013123:0.003848:0.012508:0.013066:0.013181:0.012604:0.011738:0.012604:0.005792:0.005330:0.007718:0.005792:0.013143:0.011738:0.012950:0.012508:0.007466:0.013066:0.006042:0.005711:0.012604:0.018049:0.005330
20-40%  among siblings  (same parents) :@0.084242:0.226976:0.480478:0.226976:0.480478:0.211220:0.084242:0.211220:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.005330:0.009329:0.013143:0.018049:0.012604:0.011738:0.012950:0.014643:0.007466:0.003848:0.013123:0.003848:0.003848:0.011738:0.012950:0.007466:0.005330:0.009331:0.007100:0.007466:0.013143:0.018049:0.012508:0.014643:0.013123:0.013143:0.005717:0.012508:0.011738:0.006523:0.007466:0.007100:0.005330
to 1/10000-  1/100000,  depending on the :@0.084242:0.243327:0.480478:0.243327:0.480478:0.227571:0.084242:0.227571:0.006523:0.012604:0.008948:0.010660:0.008409:0.010660:0.010660:0.010660:0.010660:0.010660:0.006388:0.005330:0.003633:0.010660:0.008409:0.010660:0.010660:0.010660:0.010660:0.010660:0.010660:0.005330:0.005330:0.003637:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.003848:0.011738:0.012950:0.008948:0.012604:0.011738:0.008948:0.006523:0.011738:0.012508:0.005330
genetic diversity of the community. High-:@0.084242:0.259678:0.475163:0.259678:0.475163:0.243922:0.084242:0.243922:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.007226:0.013181:0.003848:0.010660:0.012508:0.005792:0.007466:0.003860:0.006523:0.010314:0.007235:0.012604:0.006042:0.007235:0.006523:0.011738:0.012508:0.007235:0.012450:0.012604:0.018049:0.018049:0.011699:0.011738:0.003848:0.006523:0.010314:0.005330:0.007226:0.013143:0.003848:0.012950:0.011738:0.006388
dose therapy or immunosuppressive con-:@0.084242:0.276029:0.475163:0.276029:0.475163:0.260273:0.084242:0.260273:0.013181:0.012604:0.007466:0.012508:0.007216:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007216:0.012604:0.005792:0.007216:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.007466:0.011699:0.013123:0.013123:0.005713:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.007229:0.012450:0.012604:0.011738:0.006388
ditioning and stem-cell transplantation :@0.084242:0.292381:0.480482:0.292381:0.480482:0.276625:0.084242:0.276625:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.003848:0.011738:0.012950:0.016029:0.013143:0.011738:0.013181:0.016029:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.016029:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
are  associated  with  procedure-related :@0.084242:0.308732:0.480480:0.308732:0.480480:0.292976:0.084242:0.292976:0.013143:0.005715:0.012508:0.005330:0.009937:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.009939:0.015990:0.003848:0.006523:0.011738:0.005330:0.009937:0.013123:0.005715:0.012604:0.012450:0.012508:0.013181:0.011699:0.005711:0.012508:0.006388:0.005711:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330
mortality of 10-20% and depending on the :@0.084242:0.325083:0.480492:0.325083:0.480492:0.309327:0.084242:0.309327:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.004955:0.012604:0.006042:0.004951:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.004965:0.013143:0.011738:0.013181:0.004965:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.003848:0.011738:0.012950:0.004955:0.012604:0.011738:0.004949:0.006523:0.011738:0.012508:0.005330
mentioned risk factors, disease recurrence :@0.084242:0.341434:0.480492:0.341434:0.480492:0.325678:0.084242:0.325678:0.018049:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738:0.012508:0.013181:0.004720:0.005792:0.003848:0.007466:0.009660:0.004734:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.004720:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012519:0.004734:0.005713:0.012508:0.012450:0.011699:0.005792:0.005703:0.012508:0.011738:0.012450:0.012508:0.005330
of 15-30%.  Thus, selection criteria from :@0.084242:0.357786:0.480489:0.357875:0.480489:0.342119:0.084242:0.342030:0.012604:0.006042:0.012508:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.005330:0.006226:0.012508:0.008197:0.011738:0.011699:0.007466:0.005330:0.012508:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.012508:0.012450:0.005792:0.003848:0.006523:0.012508:0.005792:0.003848:0.013143:0.012508:0.006042:0.005711:0.012604:0.018049:0.481758
7:@0.184677:0.352256:0.190892:0.352256:0.190892:0.343070:0.184677:0.343070:0.006215
various co-operative  groups, such as Eu-:@0.084234:0.374226:0.475163:0.374226:0.475163:0.358470:0.084234:0.358470:0.010660:0.013143:0.005792:0.003848:0.012604:0.011699:0.007466:0.008467:0.012450:0.012604:0.006388:0.012604:0.013123:0.012508:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.003123:0.012950:0.005709:0.012604:0.011699:0.013123:0.007466:0.005330:0.008467:0.007466:0.011699:0.012450:0.011738:0.008467:0.013143:0.007466:0.008467:0.010314:0.011699:0.006388
ropean Bone Marrow Transplantation So-:@0.084234:0.390577:0.475153:0.390577:0.475153:0.374822:0.084234:0.374822:0.005713:0.012604:0.013123:0.012508:0.013143:0.011738:0.008178:0.011045:0.012604:0.011738:0.012508:0.008178:0.017684:0.013143:0.005792:0.005709:0.012604:0.015990:0.008178:0.007618:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.008178:0.009583:0.012604:0.006388
ciety (EBMT criteria) have been proposed :@0.084234:0.406929:0.480454:0.406929:0.480454:0.391173:0.084234:0.391173:0.012450:0.003848:0.012508:0.006523:0.010314:0.006331:0.007100:0.010314:0.011045:0.017684:0.008197:0.006331:0.012450:0.005792:0.003848:0.006523:0.012508:0.005792:0.003848:0.013143:0.007100:0.006331:0.011738:0.013143:0.010660:0.012508:0.006331:0.013123:0.012508:0.012508:0.011738:0.006331:0.013123:0.005715:0.012604:0.013123:0.012604:0.007466:0.012508:0.013181:0.005330
to assist in the selection of patients who will :@0.084234:0.423280:0.480487:0.423280:0.480487:0.407524:0.084234:0.407524:0.006523:0.012604:0.004330:0.013143:0.007466:0.007466:0.003848:0.007466:0.006537:0.004330:0.003848:0.011738:0.004330:0.006523:0.011738:0.012508:0.004330:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.004330:0.012604:0.006042:0.004330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004330:0.015990:0.011738:0.012604:0.004330:0.015990:0.003848:0.003848:0.003848:0.005330
benefit  most  from  this  procedure.  Hap-:@0.084234:0.439631:0.475151:0.439659:0.475151:0.423903:0.084234:0.423875:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.003754:0.018049:0.012604:0.007466:0.006523:0.005330:0.003760:0.006042:0.005713:0.012604:0.018049:0.005330:0.003760:0.006523:0.011738:0.003848:0.007466:0.005330:0.003766:0.013123:0.005715:0.012604:0.012450:0.012508:0.013181:0.011699:0.005711:0.012508:0.005330:0.012433:0.009102:0.013143:0.013143:0.013123:0.369195
10:@0.407818:0.434040:0.420248:0.434040:0.420248:0.424855:0.407818:0.424855:0.006215:0.006215
loidentical stem-cell transplantation with :@0.084242:0.456010:0.480462:0.456010:0.480462:0.440254:0.084242:0.440254:0.003848:0.012604:0.003848:0.013181:0.012508:0.011738:0.006523:0.003848:0.012450:0.013143:0.003848:0.010256:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.010256:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.010256:0.015990:0.003848:0.006523:0.011738:0.005330
post-transplant high-dose cyclophospha-:@0.084242:0.472362:0.475151:0.472362:0.475151:0.456606:0.084242:0.456606:0.013123:0.012604:0.007466:0.006523:0.006388:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.009179:0.011738:0.003848:0.012950:0.011738:0.006388:0.013181:0.012604:0.007466:0.012508:0.009179:0.012450:0.010314:0.012450:0.003848:0.012604:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.013143:0.006388
mide is emerging as a viable alternative :@0.084242:0.488713:0.480464:0.488713:0.480464:0.472957:0.084242:0.472957:0.018049:0.003848:0.013181:0.012508:0.008351:0.003848:0.007466:0.008351:0.012508:0.018049:0.012508:0.005804:0.012950:0.003848:0.011738:0.012950:0.008351:0.013143:0.007466:0.008351:0.013143:0.008351:0.010660:0.003848:0.013143:0.013123:0.003848:0.012521:0.008351:0.013143:0.003848:0.006523:0.012508:0.006192:0.011738:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330
for those who lack HLA-compatible do-:@0.084242:0.505064:0.475151:0.505064:0.475151:0.489308:0.084242:0.489308:0.006042:0.012604:0.005792:0.010429:0.006523:0.011738:0.012604:0.007466:0.012508:0.010429:0.015990:0.011738:0.012604:0.010429:0.003848:0.013143:0.012450:0.009660:0.010429:0.013143:0.008890:0.014239:0.006388:0.012450:0.012604:0.018049:0.013123:0.013143:0.006523:0.003848:0.013123:0.003848:0.012508:0.010429:0.013181:0.012604:0.006388
nors, although long-term survival data are :@0.084242:0.521415:0.480487:0.521415:0.480487:0.505659:0.084242:0.505659:0.011738:0.012604:0.005792:0.007466:0.005330:0.005659:0.013143:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.005659:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006313:0.018049:0.005677:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005677:0.013181:0.013143:0.006523:0.013143:0.005677:0.013143:0.005715:0.012508:0.005330
still unavailable.:@0.084242:0.537767:0.231138:0.537767:0.231138:0.522011:0.084242:0.522011:0.007466:0.006523:0.003848:0.003848:0.003848:0.005330:0.011699:0.011738:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.005330
ADULT ACUTE LYMPHOBLASTIC :@0.084242:0.571161:0.429494:0.571161:0.429494:0.551564:0.084242:0.551564:0.017404:0.016463:0.015052:0.010348:0.009878:0.006585:0.017404:0.018344:0.015052:0.009878:0.012230:0.006585:0.010348:0.014581:0.021167:0.013170:0.015993:0.019756:0.013641:0.010348:0.017404:0.012230:0.009878:0.006585:0.018344:0.006585
LEUKAEMIA:@0.084242:0.590450:0.211242:0.590450:0.211242:0.570853:0.084242:0.570853:0.010348:0.012230:0.015052:0.014581:0.017404:0.012230:0.021167:0.006585:0.017404
Adult acute lymphoblastic leukaemia (ALL) :@0.084242:0.609107:0.480486:0.609107:0.480486:0.593351:0.084242:0.593351:0.014047:0.012989:0.011507:0.003656:0.006331:0.004330:0.012950:0.012257:0.011507:0.006331:0.012315:0.004330:0.003656:0.010122:0.017857:0.012931:0.011545:0.012411:0.012931:0.003656:0.012950:0.007274:0.006331:0.003656:0.012257:0.004330:0.003656:0.012315:0.011507:0.009467:0.012950:0.012315:0.017857:0.003656:0.012950:0.004330:0.006908:0.014047:0.008698:0.008698:0.007104:0.005330
is a discrete clonal malignant disorder that :@0.084242:0.625458:0.480467:0.625458:0.480467:0.609702:0.084242:0.609702:0.003656:0.007274:0.005761:0.012950:0.005763:0.012989:0.003656:0.007274:0.012257:0.005519:0.012315:0.006331:0.012315:0.005761:0.012257:0.003656:0.012411:0.011545:0.012950:0.003656:0.005763:0.017857:0.012950:0.003656:0.003656:0.012758:0.011545:0.012950:0.011545:0.006331:0.005761:0.012989:0.003656:0.007274:0.012411:0.005482:0.012989:0.012315:0.005600:0.005761:0.006331:0.011545:0.012950:0.006521:0.005330
affects an early lymphoid progenitor (see :@0.084242:0.641810:0.480494:0.641810:0.480494:0.626054:0.084242:0.626054:0.012950:0.005905:0.005850:0.012315:0.012257:0.006331:0.007274:0.007851:0.012950:0.011545:0.007851:0.012315:0.012950:0.005600:0.003656:0.010122:0.007851:0.003656:0.010122:0.017857:0.012931:0.011545:0.012411:0.003656:0.012989:0.007851:0.012931:0.005519:0.012411:0.012758:0.012315:0.011545:0.003656:0.006331:0.012411:0.005600:0.007851:0.006908:0.007274:0.012315:0.012506:0.005330
Figure 1) and represents a heterogeneous :@0.084242:0.658161:0.480532:0.658161:0.480532:0.642405:0.084242:0.642405:0.009140:0.003656:0.012758:0.011507:0.005521:0.012315:0.006831:0.010468:0.006908:0.006831:0.012950:0.011545:0.012989:0.006831:0.005519:0.012315:0.012931:0.005521:0.012315:0.007274:0.012315:0.011545:0.006331:0.007274:0.006831:0.012950:0.006831:0.011545:0.012315:0.006331:0.012315:0.005521:0.012411:0.012758:0.012315:0.011545:0.012315:0.012411:0.011507:0.007468:0.005330
group  of  diseases that have  distinct  phe-:@0.084242:0.674512:0.475169:0.674512:0.475169:0.658756:0.084242:0.658756:0.012758:0.005521:0.012411:0.011507:0.012931:0.005330:0.002973:0.012411:0.005850:0.005330:0.002973:0.012989:0.003656:0.007274:0.012315:0.012950:0.007274:0.012315:0.007274:0.008313:0.006331:0.011545:0.012950:0.006331:0.008313:0.011545:0.012950:0.010468:0.012315:0.005330:0.002973:0.012989:0.003656:0.007274:0.006331:0.003656:0.011545:0.012257:0.006331:0.005330:0.002973:0.012931:0.011545:0.012315:0.006388
notypes and variable outcomes. Although :@0.084242:0.690863:0.480480:0.690863:0.480480:0.675107:0.084242:0.675107:0.011545:0.012411:0.006331:0.010122:0.012931:0.012315:0.007274:0.006119:0.012950:0.011545:0.012989:0.006119:0.010468:0.012950:0.005600:0.003656:0.012950:0.012931:0.003656:0.012315:0.006119:0.012411:0.011507:0.006331:0.012257:0.012411:0.017857:0.012315:0.007274:0.005138:0.006119:0.014047:0.003656:0.006331:0.011545:0.012411:0.011507:0.012758:0.011736:0.005330
there are no local data regarding the in-:@0.084242:0.707215:0.475219:0.707215:0.475219:0.691459:0.084242:0.691459:0.006331:0.011545:0.012315:0.005521:0.012315:0.008043:0.012950:0.005521:0.012315:0.008043:0.011545:0.012411:0.008043:0.003656:0.012411:0.012257:0.012950:0.003656:0.008043:0.012989:0.012950:0.006331:0.012950:0.008043:0.005519:0.012315:0.012758:0.012950:0.005482:0.012989:0.003656:0.011545:0.012758:0.008043:0.006331:0.011545:0.012315:0.008043:0.003656:0.011545:0.006388
cidence of ALL, in the US there were 5 960 :@0.084242:0.723566:0.480576:0.723566:0.480576:0.707810:0.084242:0.707810:0.012257:0.003656:0.012989:0.012315:0.011545:0.012257:0.012315:0.006177:0.012411:0.005850:0.006177:0.014047:0.008698:0.008698:0.005138:0.006177:0.003656:0.011545:0.006177:0.006331:0.011545:0.012315:0.006177:0.012411:0.009390:0.006177:0.006331:0.011545:0.012315:0.005519:0.012315:0.006177:0.015798:0.012315:0.005521:0.012315:0.006177:0.010468:0.006177:0.010468:0.010468:0.010664:0.005330
new cases in 2017.  Depending on the line-:@0.084242:0.739917:0.475162:0.739962:0.475162:0.724206:0.084242:0.724161:0.011545:0.012315:0.015798:0.004124:0.012257:0.012950:0.007274:0.012315:0.007274:0.004124:0.003656:0.011545:0.004124:0.010468:0.010468:0.010468:0.010468:0.005330:0.012035:0.004124:0.014124:0.012315:0.012931:0.012315:0.011545:0.012989:0.003656:0.011545:0.012758:0.004124:0.012411:0.011545:0.004124:0.006331:0.011545:0.012315:0.004124:0.003656:0.003656:0.011545:0.012315:-0.067619
11:@0.250570:0.734343:0.262888:0.734343:0.262888:0.725157:0.250570:0.725157:0.006103:0.006215
age, they are classified as precursor T-cell :@0.084249:0.756313:0.480491:0.756313:0.480491:0.740557:0.084249:0.740557:0.012950:0.012758:0.012315:0.005138:0.007197:0.006331:0.011545:0.012315:0.010122:0.007197:0.012950:0.005521:0.012315:0.007197:0.012257:0.003656:0.012950:0.007274:0.007274:0.003656:0.004589:0.004589:0.012315:0.012989:0.007197:0.012950:0.007274:0.007199:0.012931:0.005519:0.012315:0.012257:0.011507:0.005600:0.007274:0.012411:0.005600:0.007199:0.008005:0.006196:0.012257:0.012315:0.003656:0.003852:0.005330
and precursor B-cell leukaemias, implying a :@0.084249:0.772664:0.480508:0.772664:0.480508:0.756908:0.084249:0.756908:0.012950:0.011545:0.012989:0.004137:0.012931:0.005521:0.012315:0.012257:0.011507:0.005600:0.007274:0.012411:0.005600:0.004137:0.010853:0.006196:0.012257:0.012315:0.003656:0.003656:0.004137:0.003656:0.012315:0.011507:0.009467:0.012950:0.012315:0.017857:0.003656:0.012950:0.007274:0.005138:0.004137:0.003656:0.017857:0.012931:0.003656:0.010122:0.003656:0.011545:0.012758:0.004137:0.013144:0.005330
thymic or bone-marrow origin of malignant :@0.084249:0.789016:0.480523:0.789016:0.480523:0.773260:0.084249:0.773260:0.006331:0.011545:0.010122:0.017857:0.003656:0.012257:0.004859:0.012411:0.005600:0.004859:0.012931:0.012411:0.011545:0.012315:0.006196:0.017857:0.012950:0.005600:0.005521:0.012411:0.015798:0.004868:0.012411:0.005600:0.003656:0.012758:0.003656:0.011545:0.004859:0.012411:0.005850:0.004859:0.017857:0.012950:0.003656:0.003656:0.012758:0.011545:0.012950:0.011545:0.006521:0.005330
lymphocytes.  The pathogenesis of malig-:@0.084249:0.805367:0.475176:0.805389:0.475176:0.789633:0.084249:0.789611:0.003656:0.010122:0.017857:0.012931:0.011545:0.012411:0.012257:0.010122:0.006331:0.012315:0.007274:0.005330:0.005906:0.008043:0.008005:0.011545:0.012315:0.008043:0.012931:0.012950:0.006331:0.011545:0.012411:0.012758:0.012315:0.011545:0.012315:0.007274:0.003656:0.007274:0.008043:0.012411:0.005850:0.008043:0.017857:0.012950:0.003656:0.003656:0.012758:-0.162800
3:@0.206201:0.799770:0.212416:0.799770:0.212416:0.790585:0.206201:0.790585:0.006215
nant transformation remains unclear, but :@0.084248:0.821740:0.480531:0.821740:0.480531:0.805984:0.084248:0.805984:0.011545:0.012950:0.011545:0.006331:0.010179:0.006331:0.005600:0.012950:0.011545:0.007274:0.005850:0.012411:0.006133:0.017857:0.012950:0.006331:0.003656:0.012411:0.011545:0.010179:0.005521:0.012315:0.017857:0.012950:0.003656:0.011545:0.007274:0.010179:0.011507:0.011545:0.012257:0.003656:0.012315:0.012950:0.003575:0.005138:0.010179:0.012931:0.011507:0.006521:0.005330
genomic instability leading to chromosom-:@0.084248:0.838092:0.475174:0.838092:0.475174:0.822336:0.084248:0.822336:0.012758:0.012315:0.011545:0.012411:0.017857:0.003656:0.012257:0.005369:0.003656:0.011545:0.007274:0.006331:0.012950:0.012931:0.003656:0.003656:0.003656:0.006331:0.010122:0.005369:0.003656:0.012315:0.012950:0.012989:0.003656:0.011545:0.012758:0.005369:0.006331:0.012411:0.005369:0.012257:0.011545:0.005521:0.012411:0.017857:0.012411:0.007274:0.012411:0.017857:0.006388
al  translocations  and  mutations  of  genes :@0.084248:0.854443:0.480503:0.854443:0.480503:0.838687:0.084248:0.838687:0.012950:0.003656:0.005330:0.003893:0.006331:0.005600:0.012950:0.011545:0.007274:0.003656:0.012411:0.012257:0.012950:0.006331:0.003656:0.012411:0.011545:0.007274:0.005330:0.003893:0.012950:0.011545:0.012989:0.005330:0.003895:0.017857:0.011507:0.006331:0.012950:0.006331:0.003656:0.012411:0.011545:0.007274:0.005330:0.003893:0.012411:0.005850:0.005330:0.003895:0.012758:0.012315:0.011545:0.012315:0.007468:0.005330
associated with control of cell proliferation :@0.084248:0.870794:0.480499:0.870794:0.480499:0.855038:0.084248:0.855038:0.012950:0.007274:0.007274:0.012411:0.012257:0.003656:0.012950:0.006331:0.012315:0.012989:0.005975:0.015798:0.003656:0.006331:0.011545:0.005975:0.012257:0.012411:0.011545:0.006331:0.005519:0.012411:0.003656:0.005975:0.012411:0.005850:0.005984:0.012257:0.012315:0.003656:0.003656:0.005975:0.012931:0.005521:0.012411:0.003656:0.003656:0.005850:0.012315:0.005600:0.012950:0.006331:0.003656:0.012411:0.011736:0.005330
and apoptosis are likely. Human T-cell leu-:@0.084248:0.887145:0.475174:0.887145:0.475174:0.871389:0.084248:0.871389:0.012950:0.011545:0.012989:0.006619:0.012950:0.012931:0.012411:0.012931:0.006331:0.012411:0.007274:0.003656:0.007274:0.006619:0.012950:0.005521:0.012315:0.006619:0.003656:0.003656:0.009467:0.012315:0.003656:0.010122:0.005138:0.006619:0.012950:0.011507:0.017857:0.012950:0.011545:0.006619:0.008005:0.006196:0.012257:0.012315:0.003656:0.003656:0.006619:0.003656:0.012315:0.011507:0.006388
kaemia virus 1 has also been described in :@0.084248:0.903497:0.480447:0.903497:0.480447:0.887741:0.084248:0.887741:0.009467:0.012950:0.012315:0.017857:0.003656:0.012950:0.006831:0.010468:0.003656:0.005600:0.011507:0.007274:0.006831:0.010468:0.006831:0.011545:0.012950:0.007274:0.006831:0.012950:0.003656:0.007274:0.012411:0.006831:0.012931:0.012315:0.012315:0.011545:0.006831:0.012989:0.012315:0.007274:0.012257:0.005600:0.003656:0.012931:0.012315:0.012989:0.006831:0.003656:0.011736:0.005330
T-cell  malignancies  in  some  patients  from :@0.084248:0.919848:0.480476:0.919848:0.480476:0.904092:0.084248:0.904092:0.008005:0.006196:0.012257:0.012315:0.003656:0.003656:0.005330:0.003106:0.017857:0.012950:0.003656:0.003656:0.012758:0.011545:0.012950:0.011545:0.012257:0.003656:0.012315:0.007274:0.005330:0.003104:0.003656:0.011545:0.005330:0.003104:0.007274:0.012411:0.017857:0.012315:0.005330:0.003104:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.005330:0.003104:0.005850:0.005521:0.012411:0.018047:0.005330
Asian countries and the Caribbean basin. :@0.084248:0.936199:0.480485:0.936199:0.480485:0.920443:0.084248:0.920443:0.014047:0.007274:0.003656:0.012950:0.011545:0.007370:0.012257:0.012411:0.011507:0.011545:0.006331:0.005600:0.003656:0.012315:0.007274:0.007370:0.012950:0.011545:0.012989:0.007370:0.006331:0.011545:0.012315:0.007370:0.015452:0.012950:0.005600:0.003656:0.012931:0.012931:0.012315:0.012950:0.011545:0.007370:0.012931:0.012950:0.007274:0.003656:0.011545:0.005328:0.005330
Epstein Barr virus has also been associated :@0.523648:0.096121:0.919870:0.096121:0.919870:0.080365:0.523648:0.080365:0.010122:0.012931:0.007274:0.006331:0.012315:0.003656:0.011545:0.005907:0.010853:0.012950:0.005600:0.005600:0.005907:0.010468:0.003656:0.005600:0.011507:0.007274:0.005907:0.011545:0.012950:0.007274:0.005907:0.012950:0.003656:0.007274:0.012411:0.005907:0.012931:0.012315:0.012315:0.011545:0.005907:0.012950:0.007274:0.007274:0.012411:0.012257:0.003656:0.012950:0.006331:0.012315:0.013183:0.005330
with a B-cell leukaemia in immunocompe-:@0.523648:0.112538:0.914519:0.112538:0.914519:0.096782:0.523648:0.096782:0.015798:0.003656:0.006331:0.011545:0.006158:0.012950:0.006158:0.010853:0.006196:0.012257:0.012315:0.003656:0.003656:0.006158:0.003656:0.012315:0.011507:0.009467:0.012950:0.012315:0.017857:0.003656:0.012950:0.006158:0.003656:0.011545:0.006158:0.003656:0.017857:0.017857:0.011507:0.011545:0.012411:0.012257:0.012411:0.017857:0.012931:0.012315:0.006388
tent patients and subjects with immunode-:@0.523648:0.128955:0.914559:0.128955:0.914559:0.113199:0.523648:0.113199:0.006331:0.012315:0.011545:0.006331:0.005222:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.005224:0.012950:0.011545:0.012989:0.005222:0.007274:0.011507:0.012931:0.003714:0.012315:0.012257:0.006331:0.007274:0.005222:0.015798:0.003656:0.006331:0.011545:0.005222:0.003656:0.017857:0.017857:0.011507:0.011545:0.012411:0.012989:0.012315:0.006388
ficiency virus infection.:@0.523648:0.145373:0.728656:0.145373:0.728656:0.129617:0.523648:0.129617:0.004589:0.004589:0.012257:0.003656:0.012315:0.011545:0.012257:0.010122:0.005138:0.010468:0.003656:0.005600:0.011507:0.007274:0.005138:0.003656:0.011545:0.005850:0.012315:0.012257:0.006331:0.003656:0.012411:0.011545:0.005330
CLINICAL PRESENTATION:@0.523636:0.178561:0.772504:0.178561:0.772504:0.160746:0.523636:0.160746:0.016677:0.009407:0.005987:0.015822:0.005987:0.016677:0.015822:0.009407:0.005987:0.011973:0.012401:0.011118:0.011118:0.011118:0.015822:0.008980:0.015822:0.008980:0.005987:0.017960:0.015822
ALL  typically presents  in  children  and :@0.523636:0.196122:0.919870:0.196122:0.919870:0.180366:0.523636:0.180366:0.014239:0.008890:0.008890:0.005330:0.009812:0.006523:0.010314:0.013123:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.015163:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.007466:0.005330:0.009817:0.003848:0.011738:0.005330:0.009821:0.012450:0.011738:0.003848:0.003848:0.013181:0.005719:0.012508:0.011738:0.005330:0.009814:0.013143:0.011738:0.013181:0.005330
young  adults, being  the  most  common :@0.523636:0.212540:0.919897:0.212540:0.919897:0.196784:0.523636:0.196784:0.010314:0.012604:0.011699:0.011738:0.012950:0.005330:0.005734:0.013143:0.013181:0.011699:0.003848:0.006523:0.007466:0.005330:0.011084:0.013123:0.012508:0.003848:0.011738:0.012950:0.005330:0.005744:0.006523:0.011738:0.012508:0.005330:0.005736:0.018049:0.012604:0.007466:0.006523:0.005330:0.005744:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330
paediatric cancer,  although  older  pa-:@0.523636:0.228957:0.914543:0.228957:0.914543:0.213201:0.523636:0.213201:0.013123:0.013143:0.012508:0.013181:0.003848:0.013143:0.006523:0.005792:0.003848:0.012450:0.014297:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.005330:0.008952:0.013143:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011728:0.005330:0.008955:0.012604:0.003848:0.013181:0.012508:0.005792:0.005330:0.008952:0.013123:0.013143:0.006388
tients may also develop this malignancy.  :@0.523636:0.245375:0.919875:0.245366:0.919875:0.229610:0.523636:0.229619:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005349:0.018049:0.013143:0.010314:0.005349:0.013143:0.003848:0.007466:0.012604:0.005349:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.005349:0.006523:0.011738:0.003848:0.007466:0.005349:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.010314:0.005330:0.012430:0.206022
11:@0.902110:0.239747:0.914540:0.239747:0.914540:0.230561:0.902110:0.230561:0.006215:0.006215
Younger  patients  may present  with  sys-:@0.523635:0.261783:0.914537:0.261783:0.914537:0.246027:0.523635:0.246027:0.009677:0.012604:0.011699:0.011738:0.012950:0.012508:0.005792:0.005330:0.006304:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.006319:0.018049:0.013143:0.010314:0.011661:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.005330:0.006315:0.015990:0.003848:0.006523:0.011738:0.005330:0.006321:0.007466:0.010314:0.007466:0.006388
temic manifestations of disease, including :@0.523635:0.278201:0.919855:0.278201:0.919855:0.262445:0.523635:0.262445:0.006523:0.012508:0.018049:0.003848:0.012450:0.005869:0.018049:0.013143:0.011738:0.003848:0.006042:0.012508:0.007466:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005869:0.012604:0.006042:0.005869:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005869:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330
fever of unknown origin and joint pains, :@0.523635:0.294618:0.919882:0.294618:0.919882:0.278862:0.523635:0.278862:0.006042:0.012508:0.010660:0.012508:0.005792:0.009583:0.012604:0.006042:0.009583:0.011699:0.011738:0.009660:0.011738:0.012592:0.015990:0.011738:0.009583:0.012604:0.005792:0.003848:0.012950:0.003848:0.011738:0.009583:0.013143:0.011738:0.013181:0.009583:0.003906:0.012604:0.003848:0.011738:0.006523:0.009583:0.013123:0.013143:0.003848:0.011738:0.007466:0.005330:0.005330
associated with leukopaenia or pancyto-:@0.523635:0.311035:0.914556:0.311035:0.914556:0.295279:0.523635:0.295279:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.007004:0.015990:0.003848:0.006523:0.011738:0.006995:0.003848:0.012508:0.011699:0.009660:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.007004:0.012604:0.005792:0.006987:0.013123:0.013143:0.011738:0.012450:0.010314:0.006523:0.012604:0.006388
paenia. More  often  they  have  palpable :@0.523635:0.327453:0.919865:0.327453:0.919865:0.311697:0.523635:0.311697:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.009044:0.017684:0.012604:0.005707:0.012508:0.005330:0.003700:0.012604:0.006042:0.006523:0.012508:0.011738:0.005330:0.003693:0.006523:0.011738:0.012508:0.010314:0.005330:0.003698:0.011738:0.013143:0.010660:0.012508:0.005330:0.003704:0.013123:0.013143:0.003848:0.013123:0.013143:0.013123:0.003848:0.012508:0.005330
lymphadenopathy, hepatosplenomegaly :@0.523635:0.343870:0.919875:0.343870:0.919875:0.328114:0.523635:0.328114:0.003848:0.010314:0.018049:0.013123:0.011738:0.013143:0.013181:0.012508:0.011738:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314:0.005330:0.008755:0.011738:0.012508:0.013123:0.013143:0.006523:0.012604:0.007466:0.013123:0.003848:0.012508:0.011738:0.012604:0.018049:0.012508:0.012950:0.013143:0.003848:0.010314:0.005330
and  features  of  marrow  failure  such  as :@0.523635:0.360288:0.919865:0.360288:0.919865:0.344532:0.523635:0.344532:0.013143:0.011738:0.013181:0.005330:0.005761:0.006042:0.012508:0.013143:0.006523:0.011699:0.005709:0.012508:0.007466:0.005330:0.005763:0.012604:0.006042:0.005330:0.005761:0.018049:0.013143:0.005792:0.005711:0.012604:0.015990:0.005330:0.005757:0.006042:0.013143:0.003848:0.003848:0.011699:0.005711:0.012508:0.005330:0.005759:0.007466:0.011699:0.012450:0.011738:0.005330:0.005761:0.013143:0.007466:0.005330
pallor, ecchymoses and petechiae. Less :@0.523635:0.376705:0.919898:0.376705:0.919898:0.360949:0.523635:0.360949:0.013123:0.013143:0.003848:0.003848:0.012604:0.003775:0.005330:0.009910:0.012508:0.012450:0.012450:0.011738:0.010314:0.018049:0.012604:0.007466:0.012508:0.007466:0.009910:0.013143:0.011738:0.013181:0.009910:0.013123:0.012508:0.006523:0.012508:0.012450:0.011738:0.003848:0.013143:0.012508:0.005330:0.009910:0.008890:0.012508:0.007466:0.007466:0.005330
frequently (5-7%  of cases), patients may :@0.523635:0.393122:0.919863:0.393122:0.919863:0.377366:0.523635:0.377366:0.006042:0.005711:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.009333:0.007100:0.010660:0.006388:0.010660:0.014913:0.005330:0.004014:0.012604:0.006042:0.009333:0.012450:0.013143:0.007466:0.012508:0.007466:0.007100:0.005330:0.009333:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009333:0.018049:0.013143:0.010314:0.005330
present  with  cranial nerve  abnormalities :@0.523635:0.409540:0.919867:0.409540:0.919867:0.393784:0.523635:0.393784:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.005330:0.004637:0.015990:0.003848:0.006523:0.011738:0.005330:0.004643:0.012450:0.005792:0.013143:0.011738:0.003848:0.013143:0.003848:0.009987:0.011738:0.012508:0.005792:0.010660:0.012508:0.005330:0.004635:0.013143:0.013123:0.011738:0.012604:0.006319:0.018049:0.013143:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330
from  meningeal leukaemia. Due  to  the :@0.523635:0.425957:0.919902:0.425957:0.919902:0.410201:0.523635:0.410201:0.006042:0.005711:0.012604:0.018049:0.005330:0.005873:0.018049:0.012508:0.011738:0.003848:0.011738:0.012950:0.012508:0.013143:0.003848:0.011218:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.011218:0.014316:0.011699:0.012508:0.005330:0.005877:0.006523:0.012604:0.005330:0.005869:0.006523:0.011738:0.012508:0.005330
heterogeneity  of  this  disease,  precursor :@0.523635:0.442374:0.919886:0.442374:0.919886:0.426619:0.523635:0.426619:0.011738:0.012508:0.006523:0.012508:0.005703:0.012604:0.012950:0.012508:0.011738:0.012508:0.003848:0.006523:0.010314:0.005330:0.006694:0.012604:0.006042:0.005330:0.006698:0.006523:0.011738:0.003848:0.007466:0.005330:0.006706:0.013181:0.003848:0.007466:0.012508:0.013143:0.007478:0.012508:0.005330:0.005330:0.006698:0.013123:0.005715:0.012508:0.012450:0.011699:0.005792:0.007466:0.012604:0.005792:0.005330
B-  and T-cell leukaemias  are considered :@0.523635:0.458792:0.919857:0.458792:0.919857:0.443036:0.523635:0.443036:0.011045:0.006388:0.005330:0.003822:0.013143:0.011738:0.013181:0.009140:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.009140:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.007466:0.005330:0.003823:0.013143:0.005715:0.012508:0.009140:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.005330
as separate  entities.  Mediastinal masses :@0.523635:0.475209:0.919863:0.475209:0.919863:0.459453:0.523635:0.459453:0.013143:0.007466:0.010699:0.007466:0.012508:0.013123:0.013143:0.005792:0.013143:0.006523:0.012508:0.005330:0.005351:0.012508:0.011738:0.006523:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.005330:0.005355:0.017684:0.012508:0.013181:0.003848:0.013143:0.007466:0.006523:0.003848:0.011738:0.013143:0.003848:0.010699:0.018049:0.013143:0.007466:0.007466:0.012508:0.007466:0.005330
are common in T-cell leukaemia and may :@0.523635:0.491627:0.919875:0.491627:0.919875:0.475871:0.523635:0.475871:0.013143:0.005715:0.012508:0.005542:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005542:0.003848:0.011738:0.005542:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.005542:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.005542:0.013143:0.011738:0.013181:0.005542:0.018049:0.013143:0.010314:0.005330
lead to medical emergency from airway :@0.523635:0.508044:0.919857:0.508044:0.919857:0.492288:0.523635:0.492288:0.003848:0.012508:0.013143:0.013181:0.007728:0.006523:0.012604:0.007716:0.018049:0.012508:0.013181:0.003848:0.012450:0.013143:0.003848:0.007728:0.012508:0.018049:0.012508:0.005792:0.012950:0.012508:0.011738:0.012450:0.010314:0.007716:0.006042:0.005713:0.012604:0.018049:0.007716:0.013143:0.003848:0.005792:0.015990:0.013143:0.010314:0.005330
obstruction by lymphoid masses. T-ALL fre-:@0.523635:0.524461:0.914519:0.524461:0.914519:0.508706:0.523635:0.508706:0.012604:0.013123:0.007466:0.006523:0.005792:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005530:0.013123:0.010314:0.005542:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.003848:0.013181:0.005542:0.018049:0.013143:0.007466:0.007466:0.012508:0.007466:0.005330:0.005542:0.008197:0.006388:0.014239:0.008890:0.008890:0.005532:0.006042:0.005711:0.012508:0.006388
quently presents with elevated leukocyte :@0.523635:0.540879:0.919875:0.540879:0.919875:0.525123:0.523635:0.525123:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.007254:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.007466:0.007254:0.015990:0.003848:0.006523:0.011738:0.007254:0.012508:0.003848:0.012508:0.010660:0.013143:0.006523:0.012508:0.013181:0.007254:0.003848:0.012508:0.011699:0.009660:0.012604:0.012450:0.010314:0.006523:0.012508:0.005330
count, but is highly responsive to therapy. :@0.523635:0.557296:0.919855:0.557296:0.919855:0.541540:0.523635:0.541540:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330:0.006360:0.013123:0.011699:0.006523:0.006369:0.003848:0.007466:0.006381:0.011738:0.003848:0.012950:0.011738:0.003848:0.010314:0.006369:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.003848:0.010660:0.012508:0.006369:0.006523:0.012604:0.006369:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
Occasional, testicular masses may be the :@0.523635:0.573714:0.919903:0.573714:0.919903:0.557958:0.523635:0.557958:0.016722:0.012450:0.012450:0.013143:0.007466:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.006081:0.006523:0.012508:0.007466:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.006081:0.018049:0.013143:0.007466:0.007466:0.012508:0.007478:0.006069:0.018049:0.013143:0.010314:0.006081:0.013123:0.012508:0.006071:0.006523:0.011738:0.012508:0.005330
initial  complaint, or develop later during :@0.523635:0.590131:0.919886:0.590131:0.919886:0.574375:0.523635:0.574375:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.005330:0.003802:0.012450:0.012604:0.018049:0.013123:0.003848:0.013143:0.003848:0.011738:0.006523:0.005330:0.009121:0.012604:0.005792:0.009121:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.009121:0.003848:0.013143:0.006523:0.012508:0.005792:0.009121:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.005330
therapy  as both  the  CNS  and testis are :@0.523635:0.606548:0.919886:0.606548:0.919886:0.590793:0.523635:0.590793:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004549:0.013143:0.007466:0.009891:0.013123:0.012604:0.006523:0.011738:0.005330:0.004549:0.006523:0.011738:0.012508:0.005330:0.004547:0.015644:0.014239:0.009583:0.005330:0.004551:0.013143:0.011738:0.013181:0.009891:0.006523:0.012508:0.007466:0.006523:0.003848:0.007466:0.009891:0.013143:0.005715:0.012508:0.005330
sanctuaries with poor tissue penetration of :@0.523635:0.622966:0.919871:0.622966:0.919871:0.607210:0.523635:0.607210:0.007466:0.013143:0.011738:0.012450:0.006523:0.011699:0.013143:0.005792:0.003848:0.012508:0.007466:0.004945:0.015990:0.003848:0.006523:0.011738:0.004945:0.013123:0.012604:0.012604:0.005792:0.004936:0.006523:0.003848:0.007466:0.007466:0.011699:0.012508:0.004945:0.013123:0.012508:0.011738:0.012508:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.004932:0.012604:0.006042:0.005330
cytotoxic agents.:@0.523635:0.639383:0.685175:0.639383:0.685175:0.623627:0.523635:0.623627:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.005330:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330
11:@0.685157:0.633694:0.697587:0.633694:0.697587:0.624509:0.685157:0.624509:0.006215:0.006215
DIAGNOSIS:@0.523636:0.672466:0.640373:0.672466:0.640373:0.654650:0.523636:0.654650:0.014966:0.005987:0.015822:0.017960:0.015822:0.017960:0.011118:0.005987:0.011118
The differentiation of AML from acute lym-:@0.523636:0.690027:0.914565:0.690027:0.914565:0.674271:0.523636:0.674271:0.008197:0.011738:0.012508:0.005299:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005301:0.012604:0.006042:0.005311:0.014239:0.017684:0.008890:0.005299:0.006042:0.005711:0.012604:0.018049:0.005311:0.013143:0.012450:0.011699:0.006523:0.012508:0.005311:0.003848:0.010314:0.018049:0.006388
phocytic leukaemia has important thera-:@0.523636:0.706444:0.914557:0.706444:0.914557:0.690688:0.523636:0.690688:0.013123:0.011738:0.012604:0.012450:0.010314:0.006523:0.003848:0.012450:0.007418:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.007428:0.011738:0.013143:0.007466:0.007428:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.007410:0.006523:0.011738:0.012508:0.005792:0.013143:0.006388
peutic implications.  Investigations should :@0.523636:0.722861:0.919869:0.722856:0.919869:0.707100:0.523636:0.707105:0.013123:0.012508:0.011699:0.006523:0.003848:0.012450:0.007601:0.003848:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006228:0.007601:0.004349:0.011738:0.010660:0.012508:0.007466:0.006523:0.003848:0.012950:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.007601:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:-0.488503
3:@0.707220:0.717237:0.713434:0.717237:0.713434:0.708051:0.707220:0.708051:0.006215
include complete blood count with the :@0.523630:0.739273:0.919889:0.739273:0.919889:0.723517:0.523630:0.723517:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.010160:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.010160:0.013123:0.003848:0.012604:0.012604:0.013181:0.010160:0.012450:0.012604:0.011699:0.011738:0.006523:0.010160:0.015990:0.003848:0.006523:0.011738:0.010160:0.006523:0.011738:0.012508:0.005330
differential count, a chemistry panel and :@0.523630:0.755690:0.919871:0.755690:0.919871:0.739934:0.523630:0.739934:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.007466:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330:0.007451:0.013143:0.007466:0.012450:0.011738:0.012508:0.018049:0.003848:0.007466:0.006523:0.005792:0.010314:0.007466:0.013123:0.013143:0.011738:0.012508:0.003848:0.007466:0.013143:0.011738:0.013181:0.005330
coagulation studies as well  as careful :@0.523630:0.772108:0.919842:0.772108:0.919842:0.756352:0.523630:0.756352:0.012450:0.012604:0.013143:0.012950:0.011699:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.014162:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.014162:0.013143:0.007466:0.014162:0.015990:0.012508:0.003848:0.003848:0.005330:0.008844:0.013143:0.007466:0.014162:0.012450:0.013143:0.005715:0.012508:0.006042:0.011699:0.003848:0.005330
screening for evidence of active infection. :@0.523630:0.788525:0.919869:0.788525:0.919869:0.772769:0.523630:0.772769:0.007466:0.012450:0.005715:0.012508:0.012508:0.011738:0.003848:0.011738:0.012950:0.004349:0.006042:0.012604:0.005792:0.004349:0.012508:0.010660:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.004349:0.012604:0.006042:0.004349:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.004349:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330
According  to  WHO,  the  diagnosis  and :@0.523630:0.804943:0.919860:0.804943:0.919860:0.789187:0.523630:0.789187:0.014239:0.012450:0.012450:0.012604:0.005665:0.013181:0.003848:0.011738:0.012950:0.005330:0.007453:0.006523:0.012604:0.005330:0.007447:0.018473:0.013143:0.016722:0.005330:0.005330:0.007456:0.006523:0.011738:0.012508:0.005330:0.007445:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.007455:0.013143:0.011738:0.013181:0.005330
characterisation of lymphoblastic leukae-:@0.523630:0.821360:0.914531:0.821360:0.914531:0.805604:0.523630:0.805604:0.012450:0.011738:0.013143:0.005792:0.013143:0.012450:0.006523:0.012508:0.005792:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.006566:0.012604:0.006042:0.006569:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.006581:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.006388
mia is based on the  blood and marrow :@0.523630:0.837777:0.919875:0.837777:0.919875:0.822021:0.523630:0.822021:0.018049:0.003848:0.013143:0.009333:0.003848:0.007466:0.009333:0.013123:0.013143:0.007466:0.012508:0.013181:0.009333:0.012604:0.011738:0.009333:0.006523:0.011738:0.012508:0.005330:0.003993:0.013123:0.003848:0.012604:0.012604:0.013181:0.009333:0.013143:0.011738:0.013181:0.009333:0.018049:0.013143:0.005792:0.005711:0.012604:0.015990:0.005330
morphological features, as well as immu-:@0.523630:0.854195:0.914512:0.854195:0.914512:0.838439:0.523630:0.838439:0.018049:0.012604:0.005792:0.013123:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.007582:0.006042:0.012508:0.013143:0.006523:0.011699:0.005707:0.012508:0.007466:0.005330:0.007582:0.013143:0.007466:0.007582:0.015990:0.012508:0.003848:0.003848:0.007582:0.013143:0.007466:0.007582:0.003848:0.018049:0.018049:0.011699:0.006388
nophenotyping, cytogenetic analysis and :@0.523630:0.870612:0.919867:0.870612:0.919867:0.854856:0.523630:0.854856:0.011738:0.012604:0.013123:0.011738:0.012508:0.011738:0.012604:0.006523:0.010314:0.013123:0.003848:0.011738:0.012950:0.005330:0.005850:0.012450:0.010314:0.006523:0.012604:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.005852:0.013143:0.011738:0.013143:0.003848:0.010314:0.007466:0.003848:0.007466:0.005884:0.013143:0.011738:0.013181:0.005330
molecular characteristics of the malignant :@0.523630:0.887030:0.919887:0.887030:0.919887:0.871274:0.523630:0.871274:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.013143:0.005792:0.004358:0.012450:0.011738:0.013143:0.005792:0.013143:0.012450:0.006523:0.012508:0.005792:0.003848:0.007466:0.006523:0.003848:0.012450:0.007466:0.004368:0.012604:0.006042:0.004356:0.006523:0.011738:0.012508:0.004368:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.005330
clone.  Lymph-node  and mediastinal bi-:@0.523630:0.903447:0.914527:0.903415:0.914527:0.887659:0.523630:0.887691:0.012450:0.003848:0.012604:0.011738:0.012508:0.005330:0.006215:0.009852:0.008445:0.010314:0.018049:0.013123:0.011738:0.006388:0.011738:0.012604:0.013181:0.012508:0.005330:0.004512:0.013143:0.011738:0.013181:0.009852:0.018049:0.012508:0.013181:0.003848:0.013143:0.007466:0.006523:0.003848:0.011738:0.013143:0.003848:0.009852:0.013123:0.003848:-0.744734
3:@0.582105:0.897796:0.588320:0.897796:0.588320:0.888610:0.582105:0.888610:0.006215
opsy samples are also useful in some clini-:@0.523629:0.919832:0.914516:0.919832:0.914516:0.904076:0.523629:0.904076:0.012604:0.013123:0.007466:0.010314:0.005965:0.007466:0.013143:0.018049:0.013123:0.003848:0.012508:0.007466:0.005965:0.013143:0.005711:0.012508:0.005965:0.013143:0.003848:0.007466:0.012604:0.005965:0.011699:0.007466:0.012508:0.006042:0.011699:0.003848:0.005965:0.003848:0.011738:0.005965:0.007466:0.012604:0.018049:0.012508:0.005965:0.012450:0.003848:0.003848:0.011738:0.003848:0.006388
cal situations, whereas testing of the CSF :@0.523629:0.936250:0.919879:0.936250:0.919879:0.920494:0.523629:0.920494:0.012450:0.013143:0.003848:0.007793:0.007466:0.003848:0.006523:0.011699:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.007778:0.015990:0.011738:0.012508:0.005707:0.012508:0.013143:0.007466:0.007793:0.006523:0.012508:0.007466:0.006523:0.003848:0.011738:0.012950:0.007782:0.012604:0.006042:0.007778:0.006523:0.011738:0.012508:0.007776:0.015644:0.009583:0.009333:0.005330